Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Telemedicine Approaches to Evaluating Acute-phase ROP
Telemedicine Approaches to Evaluating Acute-phase ROP
Status: Enrolling
Updated:  9/27/2013
Nationwide Children's Hospital
mi
from
Columbus, OH
Telemedicine Approaches to Evaluating Acute-phase ROP
Telemedicine Approaches to Evaluating Acute-phase ROP
Status: Enrolling
Updated: 9/27/2013
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Telemedicine Approaches to Evaluating Acute-phase ROP
Telemedicine Approaches to Evaluating Acute-phase ROP
Status: Enrolling
Updated:  9/27/2013
University of Oklahoma
mi
from
Oklahoma City, OK
Telemedicine Approaches to Evaluating Acute-phase ROP
Telemedicine Approaches to Evaluating Acute-phase ROP
Status: Enrolling
Updated: 9/27/2013
University of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Telemedicine Approaches to Evaluating Acute-phase ROP
Telemedicine Approaches to Evaluating Acute-phase ROP
Status: Enrolling
Updated:  9/27/2013
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Telemedicine Approaches to Evaluating Acute-phase ROP
Telemedicine Approaches to Evaluating Acute-phase ROP
Status: Enrolling
Updated: 9/27/2013
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Telemedicine Approaches to Evaluating Acute-phase ROP
Telemedicine Approaches to Evaluating Acute-phase ROP
Status: Enrolling
Updated:  9/27/2013
Vanderbilt University
mi
from
Nashville, TN
Telemedicine Approaches to Evaluating Acute-phase ROP
Telemedicine Approaches to Evaluating Acute-phase ROP
Status: Enrolling
Updated: 9/27/2013
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Telemedicine Approaches to Evaluating Acute-phase ROP
Telemedicine Approaches to Evaluating Acute-phase ROP
Status: Enrolling
Updated:  9/27/2013
University of Texas, San Antonio
mi
from
San Antonio, TX
Telemedicine Approaches to Evaluating Acute-phase ROP
Telemedicine Approaches to Evaluating Acute-phase ROP
Status: Enrolling
Updated: 9/27/2013
University of Texas, San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Telemedicine Approaches to Evaluating Acute-phase ROP
Telemedicine Approaches to Evaluating Acute-phase ROP
Status: Enrolling
Updated:  9/27/2013
University of Utah
mi
from
Salt Lake City, UT
Telemedicine Approaches to Evaluating Acute-phase ROP
Telemedicine Approaches to Evaluating Acute-phase ROP
Status: Enrolling
Updated: 9/27/2013
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Evaluation of a New Daily Disposable Multifocal Contact Lens Design
Delefilcon A Multifocal Plus Power Lens Design Evaluation
Status: Enrolling
Updated:  10/9/2013
Alcon Call Center
mi
from
Fort Worth, TX
Evaluation of a New Daily Disposable Multifocal Contact Lens Design
Delefilcon A Multifocal Plus Power Lens Design Evaluation
Status: Enrolling
Updated: 10/9/2013
Alcon Call Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Clinical Evaluation of Hydrogels vs Silicone Hydrogel Contact Lenses
Clinical Evaluation of Hydrogels vs Silicone Hydrogel Contact Lenses
Status: Enrolling
Updated:  10/17/2013
University of California, Berkeley Clinical Research Center (UCB-CRC)
mi
from
Berkeley, CA
Clinical Evaluation of Hydrogels vs Silicone Hydrogel Contact Lenses
Clinical Evaluation of Hydrogels vs Silicone Hydrogel Contact Lenses
Status: Enrolling
Updated: 10/17/2013
University of California, Berkeley Clinical Research Center (UCB-CRC)
mi
from
Berkeley, CA
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
North Bay Eye
mi
from
Petaluma, CA
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
North Bay Eye
mi
from
Petaluma, CA
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
Martel Medical Eye Group
mi
from
Rancho Cardova, CA
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
Martel Medical Eye Group
mi
from
Rancho Cardova, CA
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
Specialty Eye Care
mi
from
Parker, CO
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
Specialty Eye Care
mi
from
Parker, CO
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
International Research Center
mi
from
Brandon, FL
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
International Research Center
mi
from
Brandon, FL
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
East Florida Eye Institute
mi
from
Stuart, FL
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
East Florida Eye Institute
mi
from
Stuart, FL
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
Clayton Eye Center
mi
from
Morrow, GA
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
Clayton Eye Center
mi
from
Morrow, GA
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
Coastal Research Associates, LLC
mi
from
Roswell, GA
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
Coastal Research Associates, LLC
mi
from
Roswell, GA
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
Chicago Research Center, Inc
mi
from
Chicago, IL
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
Chicago Research Center, Inc
mi
from
Chicago, IL
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
Chicago Cornea Consultants, LTD
mi
from
Hoffman Estates, IL
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
Chicago Cornea Consultants, LTD
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
Koffler Vision Group
mi
from
Lebanon, KY
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
Koffler Vision Group
mi
from
Lebanon, KY
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
Taustine Eye Center
mi
from
Louisville, KY
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
Taustine Eye Center
mi
from
Louisville, KY
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
Comprehensive Eye Care, Ltd/Vision Research Institute, LLC
mi
from
Washington, MO
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
Comprehensive Eye Care, Ltd/Vision Research Institute, LLC
mi
from
Washington, MO
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
Charlotte Eye, Ear, Nose & Throat Associates
mi
from
Charlotte, NC
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
Charlotte Eye, Ear, Nose & Throat Associates
mi
from
Charlotte, NC
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
Mundorf Eye Center
mi
from
Charlotte, NC
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
Mundorf Eye Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
Cornerstone Eyecare
mi
from
High Point, NC
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
Cornerstone Eyecare
mi
from
High Point, NC
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
Abrams Eye Center
mi
from
Cleveland, OH
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
Abrams Eye Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
Glaucoma Consultants and Center for Eye Research
mi
from
Mt. Pleasant, SC
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
Glaucoma Consultants and Center for Eye Research
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
Chattanooga Eye Institute
mi
from
Chattanooga, TN
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
Chattanooga Eye Institute
mi
from
Chattanooga, TN
Click here to add this to my saved trials
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated:  10/22/2013
Eye Clinics of South Texas
mi
from
San Antonio, TX
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Status: Enrolling
Updated: 10/22/2013
Eye Clinics of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Comparison of Intraocular Pressures (IOP) During Prolonged Trendelenburg Positioning in Morbidly Obese and Thin Patients
A Comparison of Intraocular Pressures (IOP) During Prolonged Trendelenburg Positioning in Morbidly Obese and Thin Patients
Status: Enrolling
Updated:  10/25/2013
William Beaumont Hospital-Royal Oak
mi
from
Royal Oak, MI
A Comparison of Intraocular Pressures (IOP) During Prolonged Trendelenburg Positioning in Morbidly Obese and Thin Patients
A Comparison of Intraocular Pressures (IOP) During Prolonged Trendelenburg Positioning in Morbidly Obese and Thin Patients
Status: Enrolling
Updated: 10/25/2013
William Beaumont Hospital-Royal Oak
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Clinical Evaluation of Two Monthly Replacement Silicone Hydrogel Contact Lenses
Clinical Evaluation of Two Monthly Replacement Silicone Hydrogel Contact Lenses
Status: Enrolling
Updated:  10/29/2013
Alcon Call Center
mi
from
Fort Worth, TX
Clinical Evaluation of Two Monthly Replacement Silicone Hydrogel Contact Lenses
Clinical Evaluation of Two Monthly Replacement Silicone Hydrogel Contact Lenses
Status: Enrolling
Updated: 10/29/2013
Alcon Call Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Effect of SIMBRINZA™ As an Added Therapy to TRAVATAN Z®
Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination As Adjunctive Therapy to Travoprost
Status: Enrolling
Updated:  10/29/2013
Alcon Call Center
mi
from
Fort Worth, TX
Effect of SIMBRINZA™ As an Added Therapy to TRAVATAN Z®
Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination As Adjunctive Therapy to Travoprost
Status: Enrolling
Updated: 10/29/2013
Alcon Call Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Effect of SIMBRINZA™ As an Added Therapy to a Prostaglandin Analogue
Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as Adjunctive Therapy to a Prostaglandin Analogue
Status: Enrolling
Updated:  10/29/2013
Alcon Call Center
mi
from
Fort Worth, TX
Effect of SIMBRINZA™ As an Added Therapy to a Prostaglandin Analogue
Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as Adjunctive Therapy to a Prostaglandin Analogue
Status: Enrolling
Updated: 10/29/2013
Alcon Call Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Lacrimal Drainage Resistance Study
Lacrimal Drainage Resistance Study
Status: Enrolling
Updated:  10/30/2013
Cleveland Clinic - Cole Eye Institute
mi
from
Cleveland, OH
Lacrimal Drainage Resistance Study
Lacrimal Drainage Resistance Study
Status: Enrolling
Updated: 10/30/2013
Cleveland Clinic - Cole Eye Institute
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
Status: Enrolling
Updated:  11/1/2013
Contact Alcon Call Center
mi
from
Fort Worth, TX
Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
Status: Enrolling
Updated: 11/1/2013
Contact Alcon Call Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Metabolic Screening in Patients With Donnai-Barrow Syndrome
Metabolic Screening in Patients With Donnai-Barrow Syndrome
Status: Enrolling
Updated:  11/7/2013
Massachusetts General Hospital
mi
from
Boston, MA
Metabolic Screening in Patients With Donnai-Barrow Syndrome
Metabolic Screening in Patients With Donnai-Barrow Syndrome
Status: Enrolling
Updated: 11/7/2013
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension.
Prospective, Randomized, Single-Center Study to Evaluate 24-hour Intraocular Pressure Control With Brinzolamide 1% /Brimonidine 0.2% Fixed Dose Combination Therapy
Status: Enrolling
Updated:  11/8/2013
Alcon Call Center
mi
from
Fort Worth, TX
Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension.
Prospective, Randomized, Single-Center Study to Evaluate 24-hour Intraocular Pressure Control With Brinzolamide 1% /Brimonidine 0.2% Fixed Dose Combination Therapy
Status: Enrolling
Updated: 11/8/2013
Alcon Call Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy
Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES)
Status: Enrolling
Updated:  11/18/2013
Tennessee Retina, P.C.
mi
from
Nashville, TN
Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy
Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES)
Status: Enrolling
Updated: 11/18/2013
Tennessee Retina, P.C.
mi
from
Nashville, TN
Click here to add this to my saved trials
Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma
Investigation of IOP Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma
Status: Enrolling
Updated:  11/21/2013
Alcon Call Center
mi
from
Fort Worth, TX
Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma
Investigation of IOP Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma
Status: Enrolling
Updated: 11/21/2013
Alcon Call Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Effect of Blue Light Filtration on Visual Performance
Effect of Blue Light Filtration on Visual Performance
Status: Enrolling
Updated:  11/22/2013
Alcon Call Center
mi
from
Fort Worth, TX
Effect of Blue Light Filtration on Visual Performance
Effect of Blue Light Filtration on Visual Performance
Status: Enrolling
Updated: 11/22/2013
Alcon Call Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty
Prospective, Randomized Comparison of Corticosteroid Dosing Regimens Following Endothelial Keratoplasty
Status: Enrolling
Updated:  11/23/2013
Price Vision Group
mi
from
Indianapolis, IN
Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty
Prospective, Randomized Comparison of Corticosteroid Dosing Regimens Following Endothelial Keratoplasty
Status: Enrolling
Updated: 11/23/2013
Price Vision Group
mi
from
Indianapolis, IN
Click here to add this to my saved trials
An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
Status: Enrolling
Updated:  12/4/2013
Contact Alcon for Trial Locations
mi
from
Fort Worth, TX
An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
Status: Enrolling
Updated: 12/4/2013
Contact Alcon for Trial Locations
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Safety Study of Latanoprost Slow Release Insert
A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety and Tolerability of Latanoprost Sustained Release (SR) Insert in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Status: Enrolling
Updated:  12/5/2013
Univ of Ky
mi
from
Lexington, KY
Safety Study of Latanoprost Slow Release Insert
A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety and Tolerability of Latanoprost Sustained Release (SR) Insert in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Status: Enrolling
Updated: 12/5/2013
Univ of Ky
mi
from
Lexington, KY
Click here to add this to my saved trials
Safety Study of Latanoprost Slow Release Insert
A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety and Tolerability of Latanoprost Sustained Release (SR) Insert in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Status: Enrolling
Updated:  12/5/2013
University of Kentucky
mi
from
Lexington, KY
Safety Study of Latanoprost Slow Release Insert
A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety and Tolerability of Latanoprost Sustained Release (SR) Insert in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Status: Enrolling
Updated: 12/5/2013
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Intra-Operative Metrics With CENTURION and INFINITI Vision Systems
Intra-Operative Metrics and Clinical Outcomes After Cataract Surgery With the CENTURION Vision System and the INFINITI Vision System
Status: Enrolling
Updated:  12/24/2013
Alcon Call Center
mi
from
Fort Worth, TX
Intra-Operative Metrics With CENTURION and INFINITI Vision Systems
Intra-Operative Metrics and Clinical Outcomes After Cataract Surgery With the CENTURION Vision System and the INFINITI Vision System
Status: Enrolling
Updated: 12/24/2013
Alcon Call Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®
Status: Enrolling
Updated:  1/3/2014
Martel Eye Medical Group
mi
from
Rancho Cordova, CA
A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®
Status: Enrolling
Updated: 1/3/2014
Martel Eye Medical Group
mi
from
Rancho Cordova, CA
Click here to add this to my saved trials
A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®
Status: Enrolling
Updated:  1/3/2014
Cincinnati Eye Institute
mi
from
Edgewood, KY
A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®
Status: Enrolling
Updated: 1/3/2014
Cincinnati Eye Institute
mi
from
Edgewood, KY
Click here to add this to my saved trials
A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®
Status: Enrolling
Updated:  1/3/2014
Associated Eye Care
mi
from
Stillwater, MN
A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®
Status: Enrolling
Updated: 1/3/2014
Associated Eye Care
mi
from
Stillwater, MN
Click here to add this to my saved trials
Safety Study Looking at the Effects of Stendra on Vision
A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Parallel Study to Assess the Effects of Avanafil (STENDRA™) on Multiple Parameters of Vision, Including, But Not Limited to Visual Acuity, Intraocular Pressure, Pupillometry, and Color Vision Discrimination, in Healthy Male Subjects
Status: Enrolling
Updated:  1/9/2014
Celerion
mi
from
Tempe, AZ
Safety Study Looking at the Effects of Stendra on Vision
A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Parallel Study to Assess the Effects of Avanafil (STENDRA™) on Multiple Parameters of Vision, Including, But Not Limited to Visual Acuity, Intraocular Pressure, Pupillometry, and Color Vision Discrimination, in Healthy Male Subjects
Status: Enrolling
Updated: 1/9/2014
Celerion
mi
from
Tempe, AZ
Click here to add this to my saved trials
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  1/13/2014
Clinical Research Facility
mi
from
Artesia, CA
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 1/13/2014
Clinical Research Facility
mi
from
Artesia, CA
Click here to add this to my saved trials
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  1/13/2014
Clinical Research Facility
mi
from
El Paso, TX
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 1/13/2014
Clinical Research Facility
mi
from
El Paso, TX
Click here to add this to my saved trials